Top

Published in:

01-02-2020 | Prostate Cancer | Original Article

Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters

Authors: G. Hatiboglu, V. Popeneciu, D. Bonekamp, M. Burtnyk, R. Staruch, S. Pahernik, G. Tosev, J. P. Radtke, J. Motsch, H. P. Schlemmer, M. Hohenfellner, J. N. Nyarangi-Dix

Published in: World Journal of Urology | Issue 2/2020

Abstract

Objectives

To evaluate the effect of intensified treatment parameters on safety, functional outcomes, and PSA after MR-Guided Transurethral Ultrasound Ablation (TULSA) of prostatic tissue.

Patients and methods

Baseline and 6-month follow-up data were collected for a single-center cohort of the multicenter Phase I (n = 14/30 at 3 sites) and Pivotal (n = 15/115 at 13 sites) trials of TULSA in men with localized prostate cancer. The Pivotal study used intensified treatment parameters (increased temperature and spatial extent of ablation coverage). The reporting site recruited the most patients to both trials, minimizing the influence of physician experience on this comparison of adverse events, urinary symptoms, continence, and erectile function between subgroups of both studies.

Results

For Phase I and TACT patients, median age was 71.0 and 67.0 years, prostate volume 41.0 and 44.5 ml, and PSA 6.7 and 6.7 ng/ml, respectively. All 14 Phase I patients had low-risk prostate cancer, whereas 7 of 15 TACT patients had intermediate-risk disease. Baseline IIEF, IPSS, quality of life, and pad use were similar between groups. Pad use at 1 month and quality of life at 3 months favored Phase I patients. At 6 months, there were no significant differences in functional outcomes or adverse events.

Conclusion

TULSA demonstrated acceptable clinical safety in Phase I trial. Intensified treatment parameters in the TACT Pivotal trial increased ablation coverage from 90 to 98% of the prostate without affecting 6-month adverse events or functional outcomes. Long-term follow-up and 12-month biopsies are needed to evaluate oncological safety.

Krebs in Deutschland 2013/2014 (2017) 11. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Robert Koch-Institut, Berlin. https://doi.org/10.17886/rkipubl-2017-007. ISBN: 978-3-89606-288-8CrossRef

Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, De Santis M, Henry A, Joniau S, Lam T, Mason MD, Van den Poel H, Van den Kwast TH, Rouvière O, Wiegel T members of the EAU–ESTRO–SUR–SIOG Prostate Cancer Guidelines Panel. EAU–ESTRO–ESUR–SIOG Guidelines on Prostate Cancer. Edn. Presented at the EAU annual congress Copenhagen 2018. ISBN:978-94-92671-02-8. EAU Guidelines Office. Place published, Arnhem, The Netherlands

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE, Protec TSG (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220 CrossRef

Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, Hatiboglu G, Mueller-Wolf MB, Motsch J, Romagnoli C, Kassam Z, Harle CC, Hafron J, Nandalur KR, Chronik BA, Burtnyk M, Schlemmer HP, Pahernik S (2016) Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol 70(3):447–455. https://doi.org/10.1016/j.eururo.2015.12.029 CrossRefPubMed

Burtnyk M, Hill T, Cadieux-Pitre H, Welch I (2015) Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup. J Urol 193(5):1669–1675. https://doi.org/10.1016/j.juro.2014.11.089 CrossRefPubMed

Chopra R, Burtnyk M, N’Djin WA, Bronskill M (2010) MRI-controlled transurethral ultrasound therapy for localised prostate cancer. Int J Hyperthermia 26(8):804–821. https://doi.org/10.3109/02656736.2010.503670 CrossRefPubMed

Partanen A, Yerram NK, Trivedi H, Dreher MR, Oila J, Hoang AN, Volkin D, Nix J, Turkbey B, Bernardo M, Haines DC, Benjamin CJ, Linehan WM, Choyke P, Wood BJ, Ehnholm GJ, Venkatesan AM, Pinto PA (2013) Magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised MRI-based moulds. BJU Int 112(4):508–516. https://doi.org/10.1111/bju.12126 CrossRefPubMed

Siddiqui K, Chopra R, Vedula S, Sugar L, Haider M, Boyes A, Musquera M, Bronskill M, Klotz L (2010) MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology 76(6):1506–1511. https://doi.org/10.1016/j.urology.2010.04.046 CrossRefPubMed

Sapareto SA, Dewey WC (1984) Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 10(6):787–800CrossRef

10.

McDannold NJ, King RL, Jolesz FA, Hynynen KH (2000) Usefulness of MR imaging-derived thermometry and dosimetry in determining the threshold for tissue damage induced by thermal surgery in rabbits. Radiology 216(2):517–523. https://doi.org/10.1148/radiology.216.2.r00au42517 CrossRefPubMed

11.

Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, Kuru TH, Popeneciu IV, Chin JL, Billia M, Relle J, Hafron J, Nandalur KR, Staruch RM, Burtnyk M, Hohenfellner M, Schlemmer HP (2018) Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. Euro Radiol 29:299–308. https://doi.org/10.1007/s00330-018-5584-y CrossRef

12.

National Cancer Institute; Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 01.02.2019

13.

Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendorfer T, Huber J, Zogal P, Teber D, Pahernik S, Roethke M, Zamecnik P, Roth W, Sakas G, Schlemmer HP, Hohenfellner M (2011) A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 186(6):2214–2220. https://doi.org/10.1016/j.juro.2011.07.102 CrossRefPubMed

14.

Klotz L, Penson D, Chin J, Pavlovich C, Relle J, Koch M, Hatiboglu G, Oto A, Futterer J, Raman SS, Lotan Y, Persigehl T, Heidenreich A, Suarez JF, Staruch R, Burtnyk M, Pantuck A, Sedelaar JP, Arora SS, Zagaja G, Tirkes T, Macura K, Bonekamp D, Haider M, Eggener S (2018) LBA20 MRI-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer: preliminary results of tact pivotal study. J Urol 199(4):e1077–e1078. https://doi.org/10.1016/j.juro.2018.03.091 CrossRef

15.

Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A (2011) Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the stuttgart failure criteria—analysis from the @-Registry. BJU Int 108(8 Pt 2):E196–E201. https://doi.org/10.1111/j.1464-410X.2011.10091.x CrossRefPubMed

16.

Chen PY, Chiang PH, Liu YY, Chuang YC, Cheng YT (2018) Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: the important predictors of biochemical recurrence. Int J Urol 25(6):615–620. https://doi.org/10.1111/iju.13581 CrossRefPubMed

17.

Baumunk D, Andersen C, Heile U, Ebbing J, Cash H, Porsch M, Liehr UB, Janitzky A, Wendler JJ, Schindele D, Blaschke S, Miller K, Schostak M (2013) High-intensity focussed ultrasound in low-risk prostate cancer—oncological outcome and postinterventional quality of life of an inexperienced therapy centre in comparison with an experienced therapy centre. Aktuelle Urol 44(4):285–292. https://doi.org/10.1055/s-0033-1348253 CrossRefPubMed

18.

Chaussy C, Thuroff S (2001) Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 15(4):437–440. https://doi.org/10.1089/089277901300189501 CrossRefPubMed

19.

Crouzet S, Chapelon JY, Rouviere O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, Martin X, Gelet A (2014) Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol 65(5):907–914. https://doi.org/10.1016/j.eururo.2013.04.039 CrossRefPubMed

20.

Netsch C, Pfeiffer D, Gross AJ (2010) Development of bladder outlet obstruction after a single treatment of prostate cancer with high-intensity focused ultrasound: experience with 226 patients. J Endourol 24(9):1399–1403. https://doi.org/10.1089/end.2009.0607 CrossRefPubMed

21.

Ohigashi T, Nakamura K, Nakashima J, Baba S, Murai M (2007) Long-term results of three different minimally invasive therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: comparison at a single institute. Int J Urol 14(4):326–330. https://doi.org/10.1111/j.1442-2042.2007.01692.x CrossRefPubMed

22.

Chopra R, Burtnyk M, Haider MA, Bronskill MJ (2005) Method for MRI-guided conformal thermal therapy of prostate with planar transurethral ultrasound heating applicators. Phys Med Biol 50(21):4957–4975. https://doi.org/10.1088/0031-9155/50/21/001 CrossRefPubMed

23.

Steele GS, Sleep DJ (1997) Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol 158(5):1834–1838CrossRef

24.

Gravas S, Laguna MP, de la Rosette JJ (2003) Efficacy and safety of intraprostatic temperature-controlled microwave thermotherapy in patients with benign prostatic hyperplasia: results of a prospective, open-label, single-center study with 1-year follow-up. J Endourol 17(6):425–430. https://doi.org/10.1089/089277903767923236 CrossRefPubMed

25.

Vesely S, Knutson T, Dicuio M, Damber JE, Dahlstrand C (2005) Transurethral microwave thermotherapy: clinical results after 11 years of use. J Endourol 19(6):730–733. https://doi.org/10.1089/end.2005.19.730 CrossRefPubMed

26.

Norby B, Nielsen HV, Frimodt-Moller PC (2002) Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int 90(9):853–862CrossRef

27.

Chaussy C, Thuroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4(3):248–252CrossRef

Title: Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters
Authors: G. Hatiboglu
V. Popeneciu
D. Bonekamp
M. Burtnyk
R. Staruch
S. Pahernik
G. Tosev
J. P. Radtke
J. Motsch
H. P. Schlemmer
M. Hohenfellner
J. N. Nyarangi-Dix
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Magnetic Resonance Imaging
Ultrasound
Magnetic Resonance Imaging
Prostate Cancer
Ultrasound
Published in: World Journal of Urology / Issue 2/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02784-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters

Abstract

Objectives

Patients and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie’s disease: a review of the literature

Preclinical comparison of superpulse thulium fiber laser and a holmium:YAG laser for lithotripsy

An evaluation of multidrug-resistant (MDR) bacteria in patients with urinary stone disease: data from a high-volume stone management center

Occupational traumatic injuries rarely affect genitourinary organs: a retrospective, comparative study

iPad-assisted percutaneous nephrolithotomy (PCNL): a matched pair analysis compared to standard PCNL

Urinary fungi associated with urinary symptom severity among women with interstitial cystitis/bladder pain syndrome (IC/BPS)